Breaking Finance News

Zacks Investment Research downgraded GenMark Diagnostics, Inc (NASDAQ:GNMK) to Hold in a report released today.

Zacks Investment Research has downgraded GenMark Diagnostics, Inc (NASDAQ:GNMK) to Hold in a report released on 9/28/2016.

Just yesterday GenMark Diagnostics, Inc (NASDAQ:GNMK) traded -2.18% lower at $11.69. GenMark Diagnostics, Inc’s 50-day moving average is $9.47 and its 200-day moving average is $7.91. The last stock price is up 47.70% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 191,535 shares of GNMK traded hands, down from an average trading volume of 341,025

Recent Performance Chart

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc has 52 week low of $4.20 and a 52 week high of $12.17 and has a market capitalization of $0.

Brief Synopsis On GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.